School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.
3B's Research Group, I3Bs Research Institute on Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Avepark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, University of Minho, 4805-017, Barco/Guimarães, Portugal.
J Cancer Res Clin Oncol. 2022 Sep;148(9):2375-2386. doi: 10.1007/s00432-022-04079-x. Epub 2022 Jun 4.
Lung cancer is the leading cause of cancer mortality worldwide. To improve the therapeutic outcomes, drug delivery systems, and particularly liposomes, have been widely investigated. Therefore, this review analyzed systematically the literature to inquire about the safety and efficacy of liposomal formulations in lung cancer treatment.
Three electronic databases (PubMed, Web of Science and Cochrane CENTRAL) were systematically searched until May 2020. Clinical trials containing information about the effects of liposomal formulations in lung cancer patients were considered eligible.
Twenty two selected studies present different treatment options for both small and non-small-cell lung cancers. After compiling and analyzing all the published information, we verified that combination of liposomal cisplatin and paclitaxel led to a statistically significant improvement of the evaluated outcomes. Moreover, tecemotide, a liposome-based immunotherapy, demonstrated lower toxicity compared to control groups. Evidences that other subgroups could benefit from this formulation were also provided.
This systematic review (registration number CRD42021246587) demonstrates that liposomal formulations are promising alternatives to overcome limitations of traditional cancer therapy. However, larger, longer, randomized and double-blinded clinical trials, selecting their patients' cohort considering more responsive subgroups would be beneficial to strengthen the scientific and clinical evidence of the results herein reported.
肺癌是全球癌症死亡的主要原因。为了改善治疗效果，药物输送系统，特别是脂质体，已被广泛研究。因此，本综述系统地分析了文献，以了解脂质体制剂在肺癌治疗中的安全性和疗效。
系统检索了三个电子数据库（PubMed、Web of Science 和 Cochrane CENTRAL），直到 2020 年 5 月。含有脂质体制剂对肺癌患者影响信息的临床试验被认为符合条件。
22 项选定的研究为小细胞和非小细胞肺癌提供了不同的治疗选择。在编译和分析所有已发表的信息后，我们验证了脂质体顺铂和紫杉醇的联合使用导致评估结果的统计学显著改善。此外，基于脂质体的免疫疗法替莫唑胺与对照组相比毒性较低。还提供了其他亚组可能受益于这种制剂的证据。
本系统综述（注册号 CRD42021246587）表明，脂质体制剂是克服传统癌症治疗局限性的有前途的替代方案。然而，更大、更长、随机和双盲临床试验，选择更具反应性的亚组来选择患者队列，将有利于加强本文报告结果的科学和临床证据。
